scramble: 38.3% 5.9%, n = 9
Started at 183 lb last February
This result was promising, but Scholar Rock appears to have discontinued their obesity program to focus on commercializing apetiogromab for SMA
For a 220-pound person, that translates to roughly 46 lbs on tirzepatide vs 33 lbs on semaglutide
Of relevance, single-measurement albuminuria outcomes were shown to be sufficient to detect the treatment effects of drugs [30, 31]
You may have a higher risk of eye-related side effects if you have: Existing eye conditions, especially diabetic retinopathy Diabetes-related eye disease High blood pressure High cholesterol Sleep apnea These conditions may also have an impact on vision, which makes it difficult to fully understand the impact of GLP-1 medications, says Dr